Elicera Therapeutics AB (8E8) AI Stock Analysis

Elicera Therapeutics AB

(Frankfurt:8E8)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetA debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.

Negative Factors

No current TTM revenueRevenue has deteriorated sharply to zero on a trailing basis, indicating that the company currently lacks a commercial revenue stream to fund operations. Until partnering proceeds, product sales, or development milestones emerge, financial performance remains highly dependent on successful pipeline advancement.

Elicera Therapeutics AB (8E8) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 16.18M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -7.5
Beta (1Y): 0.84
Revenue Growth: ―
EPS Growth: 10.71%
Country: Germany
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Elicera Therapeutics AB Business Overview & Revenue Model

Company Description

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several d...

Elicera Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8E8 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.53	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BINV	47Neutral	SEK 357.32M	-0.58	-128.54%	―	-83.67%	-50.29%
SE:ONCO	47Neutral	SEK 721.66M	-2.12	―	―	87.23%	35.27%
SE:IMMU	43Neutral	SEK 348.89M	-3.03	-18.05%	―	―	15.97%
SE:ATORX	37Underperform	SEK 35.32M	-0.02	-439.98%	―	-99.33%	64.90%

* Healthcare Sector Average

Performance Comparison

DE:8E8 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8E8	Elicera Therapeutics AB	0.21	-0.32	-59.85%
SE:ATORX	Alligator Bioscience AB	0.01	-0.36	-96.77%
SE:BINV	BioInvent International AB	4.30	-28.85	-87.03%
SE:ONCO	Oncopeptides AB	1.66	-3.81	-69.69%
SE:IMMU	Immunicum AB	5.43	-1.97	-26.62%
SE:CANTA	Cantargia AB	1.72	-1.56	-47.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Elicera Therapeutics AB AI Stock Analysis